Related Experiment Video
Updated: Aug 11, 2026
Layer-by-layer Collagen Deposition in Microfluidic Devices for Microtissue Stabilization
Published on: September 29, 2015
Can collagen metabolism be controlled: theoretical considerations
Abstract:
Pharmacologic alterations of the inflammatory response and collagen metabolism will lead to control of the many disease states of fibrosis. Many of these diseases kill and cripple far more than hypertrophic scar. Far too little research is being directed in this area. The objectives of controlling fibrosis by interfering with collagen crosslinking were defined clearly by Peacock. Perhaps topical BAPN will be the first agent to bring a practical clinical reality to his predictions made over 20 years ago.
Insights
Targeting inflammation and collagen metabolism may control fibrotic diseases. Research suggests topical beta-aminopropionitrile (BAPN) could be a practical approach to inhibiting collagen crosslinking and treating fibrosis.
Area of Science:
- Fibrosis research
- Pharmacology
- Collagen metabolism
Background:
- Fibrotic diseases pose a significant health burden, causing widespread morbidity and mortality.
- Current research into antifibrotic therapies, particularly those targeting collagen, is insufficient.
- Hypertrophic scarring is a known consequence of fibrosis, but many systemic fibrotic diseases are more debilitating.
Purpose of the Study:
- To explore pharmacologic strategies for controlling fibrotic disease states.
- To investigate the potential of interfering with collagen crosslinking as a therapeutic approach.
- To evaluate the clinical applicability of topical beta-aminopropionitrile (BAPN) in managing fibrosis.
Main Methods:
- Review of existing research on pharmacologic interventions for fibrosis.
- Analysis of Peacock's work on controlling fibrosis by inhibiting collagen crosslinking.
- Assessment of topical BAPN as a potential antifibrotic agent.
Main Results:
- Pharmacologic modulation of inflammatory response and collagen metabolism offers a pathway to control fibrotic diseases.
- Interference with collagen crosslinking is a viable objective for fibrosis control.
- Topical BAPN shows promise in realizing long-standing predictions for clinical fibrosis management.
Conclusions:
- Targeting collagen crosslinking with agents like topical BAPN represents a promising strategy for treating fibrotic diseases.
- Further research and clinical application of BAPN could lead to effective management of debilitating fibrotic conditions.
- Increased research focus on antifibrotic therapies is warranted to address the significant impact of fibrotic diseases.
